Biopharma shake-up: Semnur Pharmaceuticals to merge with Denali Capital in $2.5bn deal
In a significant development within the biopharmaceutical industry, Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. (Nasdaq: DECA, “Denali”), a special purpose acquisition company (SPAC), have announced a definitive merger agreement. This proposed business combination is set to value Semnur at approximately $2.5 […]